Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Buy" by Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have earned a consensus recommendation of "Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $23.20.

STOK has been the topic of several analyst reports. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. HC Wainwright decreased their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Finally, Chardan Capital restated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th.

Stoke Therapeutics Stock Performance

STOK traded up $0.26 on Thursday, reaching $11.14. 463,035 shares of the company's stock were exchanged, compared to its average volume of 705,353. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $17.58. The company's 50 day moving average is $8.77 and its 200-day moving average is $9.64. The company has a market cap of $608.21 million, a price-to-earnings ratio of -5.30 and a beta of 1.09.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Sell-side analysts forecast that Stoke Therapeutics will post -2.01 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now owns 63,962 shares of the company's stock, valued at $554,550.54. This trade represents a 5.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,748 shares of company stock worth $225,687 over the last three months. Company insiders own 11.30% of the company's stock.

Institutional Trading of Stoke Therapeutics

Several institutional investors have recently added to or reduced their stakes in STOK. Rhumbline Advisers raised its holdings in shares of Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock worth $545,000 after buying an additional 2,787 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after acquiring an additional 1,330 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Stoke Therapeutics by 8.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 342,129 shares of the company's stock valued at $3,774,000 after acquiring an additional 25,995 shares in the last quarter. Swiss National Bank raised its stake in Stoke Therapeutics by 20.4% during the 4th quarter. Swiss National Bank now owns 67,300 shares of the company's stock worth $742,000 after buying an additional 11,400 shares during the period. Finally, Teacher Retirement System of Texas acquired a new position in Stoke Therapeutics during the 4th quarter worth approximately $113,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.